IRVINE, Calif.--(BUSINESS WIRE)--California Stem Cell (CSC) announced today that it has acquired a cancer stem cell program that is currently focused on the treatment of metastatic melanoma. The treatment represents a novel approach to treating malignancy.
The central concept behind this treatment is immunization against antigens via cells derived from the patient’s own blood that are then exposed to the patient’s own irradiated cancer cells, and subsequently administered in a series of injections. Significantly improved survival and time to recurrence has been demonstrated in an ongoing randomized Phase II trial, laying the groundwork for an effective treatment for melanoma and other cancers.
